Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients

Patients receiving large amounts of interferon (IFN), particularly cloned IFN-alpha, have been reported to develop antibodies to IFN-alpha. We used a neutralization technique bioassay to monitor 175 patients undergoing recombinant (r) IFN-alpha 2b therapy in an attempt to correlate antibody producti...

Full description

Saved in:
Bibliographic Details
Published inJournal of interferon research Vol. 9 Suppl 1; p. S33
Main Authors Dianzani, F, Antonelli, G, Amicucci, P, Cefaro, A, Pintus, C
Format Journal Article
LanguageEnglish
Published United States 01.09.1989
Subjects
Adolescent
Adult
Aged
Antibodies - analysis
Antibodies - immunology
Antigen-Antibody Reactions
Female
Humans
Interferon Type I - immunology
Interferon-alpha - immunology
Interferon-alpha - therapeutic use
Italy
Male
Middle Aged
Multicenter Studies as Topic
Recombinant Proteins
Online AccessGet more information

Cover

More Information
Summary:Patients receiving large amounts of interferon (IFN), particularly cloned IFN-alpha, have been reported to develop antibodies to IFN-alpha. We used a neutralization technique bioassay to monitor 175 patients undergoing recombinant (r) IFN-alpha 2b therapy in an attempt to correlate antibody production to disease progression. Only 1 patient being treated for chronic myelogenic leukemia produced antibodies. Our findings indicate that rIFN-alpha 2b has minimal antigenicity, even when administered for prolonged periods of time.
ISSN:0197-8357